SYSTEMATIC REVIEW article
Front. Med.
Sec. Hepatobiliary Diseases
Efficacy of Empagliflozin in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease with or without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Provisionally accepted
- Imam Muhammad ibn Saud Islamic University, Riyadh, Saudi Arabia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has demonstrated potential hepatic benefits in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), particularly among those with type 2 diabetes mellitus (T2DM). This meta-analysis aimed to evaluate the efficacy of empagliflozin on hepatic and metabolic outcomes in patients with MASLD. Methods: A systematic literature search of PubMed, Scopus, and Web of Science was conducted up to September 2025 to identify randomized controlled trials (RCTs) evaluating empagliflozin in MASLD patients with or without T2DM. Primary outcomes included changes in liver enzymes including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), hepatic steatosis and fibrosis indices including controlled attenuation parameter (CAP), liver stiffness measurement (LSM), aspartate aminotransferase to platelet ratio index (APRI), fibrosis-4 index (FIB-4), and the MASLD fibrosis score (NFS), and secondary outcomes included lipid parameters, glycemic control, and anthropometric measures. Results: Eight RCTs involving 672 participants (353 empagliflozin and 319 placebo) were included. Empagliflozin significantly reduced ALT (mean difference [MD] = –9.36, 95% CI: –16.07 to –2.66, p = 0.006) and AST (MD = –9.09, 95% CI: –15.41 to –2.78, p = 0.005) compared to placebo. A significant reduction was also observed in triglyceride levels (MD = –29.29, 95% CI: –53.14 to –5.45, p = 0.02). No significant differences were found for CAP (MD = –5.72, p = 0.29), LSM (MD = –0.49, p = 0.38), APRI (MD = –0.02, p = 0.36), FIB-4 (MD = –0.06, p = 0.34), or NFS (MD = –0.04, p = 0.83). Similarly, no significant effects were observed for body weight, body mass index (BMI), fasting blood sugar, or glycated hemoglobin (HbA1c). Conclusion: Empagliflozin is associated with significant improvements in liver enzyme levels and a reduction in triglyceride levels in patients with MASLD. However, no clear benefit was observed in non-invasive markers of hepatic steatosis or fibrosis. Further large-scale, long-duration RCTs with histological endpoints are needed to confirm these findings and establish empagliflozin's role in MASLD management.
Keywords: empagliflozin, Metabolically-dysfunction-associated steatotic liver disease, liver enzymes, Fibrosis, SGLT2 inhibitors, Meta-analysis
Received: 24 Sep 2025; Accepted: 26 Nov 2025.
Copyright: © 2025 I. AlHussaini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Khalid I. AlHussaini
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.